Historial de carrera de Michelle Wiest
Antiguos cargos conocidos de Michelle Wiest.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Lipomics Technologies, Inc.
Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | Director Técnico/Científico/I+D | 01/01/2004 | 11/09/2009 |
Formación de Michelle Wiest.
North Dakota State University | Undergraduate Degree |
University of California, Davis | Doctorate Degree |
Estadísticas
Internacional
Estados Unidos | 4 |
Operativa
Chief Tech/Sci/R&D Officer | 1 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Sectorial
Consumer Services | 3 |
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Lipomics Technologies, Inc.
Lipomics Technologies, Inc. BiotechnologyHealth Technology Lipomics is uniquely positioned as a leader in personalized medicine for metabolic disorders. Developing diagnostics for metabolic diseases. Its research and development efforts apply proprietary techniques in lipid profiling and data interpretation to identify clinically relevant biomarkers and validate their potential for diagnostic tests. Working with strategic partners, Lipomics Technologies is advancing its goal to develop clinical diagnostic tools with an emphasis on high-density lipoprotein metabolism, diabetes, weight loss and inflammation. Its service unit provides biomarker discovery and biological consultation services for advancing drug development with their pharmaceutical partners. The company generates high-quality quantitative profiles of lipid metabolites that are central to metabolic diseases. These metabolites include eicosanoids, acylcarnitines, sterols, bile acids and structural and energetic lipids. In addition to quantitative metabolite profiling, Lipomics provides bioinformatic analysis and biological interpretation services. | Health Technology |
- Bolsa de valores
- Insiders
- Michelle Wiest
- Experiencia